Global Dry Powder Inhalation Market Developments and Products Report 2022 with Philip Morris International, British American Tobacco and Imperial Brands (Nerudia Ltd.)

DUBLIN, April 8, 2022 /PRNewswire/ — The report “Dry Powder Inhalation Developments and Products In Scope of Nicotine, Cannabinoids, Botanicals and Other Non-Medical Substances Delivery, Designed By Big Tobacco and Pharmaceutical Companies – Market Overview Report for 1994-2022” has been added to the report from offer.

Research and Markets Logo

Dry powder inhalation technology is an effective method of delivering nicotine, cannabis-based drugs, stimulants and herbal medicines by big pharma and big tobacco companies.

Philip Morris International, British American Tobacco and Imperial Brands (Nerudia Ltd.) were actively engaged in the development of dry powder inhalation technology. These companies have applied fundamentally different approaches to dry powder inhalers and their developments are at different stages: cancellation, underdevelopment, clinical trials, etc.

Dry powder inhalation technology offers a number of indisputable advantages. Dry powder formulations allow faster dissolution and absorption of nicotine/cannabis/alternative formulations. Dry powder inhalers feature a battery-free design, precise dose control, and low-cost manufacturing.

Among a variety of dry powder inhaler designs, multi-dose (reservoir) and multi-dose (blister) inhalers are considered potential pharmaceutical platforms for the inhalation delivery of nicotine, cannabis, stimulants, and botanical formulations. .

This report provides an overview of dry powder inhalation as an alternative delivery technology for nicotine, cannabis, and alternative botanicals and stimulants, as well as analysis of existing solutions and prospective designs for inhalation devices. dry powder.

Report scope

  • The first section contains a general overview and outlook for dry powder technology as an alternative for the delivery of nicotine, cannabinoids, herbs and stimulants.

  • The second section gives a detailed observation of major tobacco company approaches to dry powder inhalation technology.

  • The third section provides a list of patents related to nicotine, cannabis and alternative substances and formulations

  • The fourth section covers existing designs and prospective concepts of dry powder cannabis and nicotine inhaler devices with related patents and the main advantages and disadvantages of each type.

.Main topics covered:

Report scope


1. Prospects of dry powder inhalation technology

2. Developments of dry powder inhalation by Big Tobacco and their subsidiaries
2.1 PMI Developments in Dry Powder Inhalation
2.2 BAT Developments in Dry Powder Inhalation
2.3 Imperial Brands Dry Powder Inhalation Developments

3. Inhalable dry powder formulations
3.1 Inhalable formulations with nicotine
3.2 Inhalable formulations containing cannabinoids
3.3 Inhalable formulations with alternative substances

4. Prospective Designs of Cannabis and Nicotine Dry Powder Inhalers
4.1 Unit dose dry powder inhalers (disposable)
4.2 Unit dose (capsule) dry powder inhalers
4.3 Multi-dose dry powder inhalers (reservoir)


Companies cited

  • Advanced Inhalation Res Inc.

  • Advanced Therapeutic Products, Inc.

  • Advent Pharmaceuticals Pty Ltd.

  • Aerodesigns, Inc.

  • Aspira Ltd.

  • Aespironics Ltd.

  • Almirall Sa

  • Asta Medica AG

  • Ab Astra

  • Aventis Pharma Ltd.

  • Bang & Olufsen Medicom as

  • Bespak plc

  • Boehringer Ingelheim Pharma

  • Braunform GmbH

  • Breathable Foods, Inc.

  • Britannia Pharmaceuticals Ltd.

  • British American Tobacco

  • Chiesi Farma Spa

  • cipla ltd.

  • Colorado Can LLC

  • Dictaphone Corp.

  • Dott Ltd. Co.

  • Echo Pharmaceuticals B.V.

  • Elan Pharma Inc.

  • Elpen Pharmaceutical Co. Inc.

  • Esolat Ltd.

  • Euro-Celtic SA

  • Fisons Pharmaceuticals Ltd

  • Flurry Powders, LLC

  • Gbs Global Biopharma, Inc.

  • Glaxo Group Ltd.

  • Hanmi Pharm Ind Co. Ltd.

  • Hovione Inter AG

  • Ab Iconovo

  • Imperial Marks

  • Inhaled therapy system

  • Innovata Biomed Ltd.

  • LLC Innovative Devices

  • Island Breeze Systems CA, LLC

  • Japan Tobacco International

  • Protecsom Laboratory, Sas

  • SMBSA Laboratories

  • Lovelace Respiratory Research

  • Mannkind Corp.

  • Manta Devices, LLC

  • Meadwestvaco Calmar GmbH

  • Mederio AG

  • Medpharm Holdings, LLC

  • Merica Ltd.

  • Miat Spa

  • Microdrug AG

  • Therapeutic Nektar

  • Nerudia Ltd.

  • Novartis Pharmaceuticals GmbH

  • Oriel Therapeutics Inc.

  • Orion Corporation

  • Otitopic Inc.

  • Otsuka Pharma Co.Ltd.

  • Pantoquimica-Sociedade Farmaceutica, Lda.

  • Pharmaceutical Discovery Society

  • Philip Morris International

  • Spa Plastiape

  • Pulmatrix, Inc.

  • Pureims SA

  • Quadrant Technologies Ltd.

  • Reddys Lab Inc.

  • Respirics Inc.

  • Sanofi SA

  • Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

  • Sansa Company (Barbados) Inc.

  • Schering Corp.

  • Skyepharma SA

  • Sofar SPA

  • Solvay Pharmaceuticals B.V.

  • Sun Pharmaceutical Ind. ltd.

  • Tff Pharmaceuticals, Inc.

  • Valois SAS

  • Vectura Ltd.

  • Vortran Medical Technology Inc.

For more information about this report visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716



View original content: – tobacco-and-imperial-brands-nerudia-ltd-301520771.html

SOURCE Research and Markets

Previous Allergies or something else? | News, Sports, Jobs
Next Citizens Bank Student Loans Review 2022 - Forbes Advisor